Technical Analysis for THRX - Theseus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 4.06 0.00% 0.00
THRX closed unchanged on Tuesday, February 13, 2024, on 6.76 times normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Flat

Date Alert Name Type % Chg
Volume Surge Other 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Bollinger Band Squeeze Range Contraction -0.25%
Narrow Range Bar Range Contraction -0.25%
Bollinger Band Squeeze Range Contraction 0.00%
Shooting Star Candlestick Bearish -0.49%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Theseus Pharmaceuticals, Inc. Description

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Organic Compounds Chemical Compounds Non Small Cell Lung Cancer Lung Cancer Protein Kinase Inhibitor Targeted Therapy Epidermal Growth Factor Receptor Tyrosine Kinase Non Small Cell Lung Carcinoma Advanced Gastrointestinal Stromal Tumors

Is THRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.37
52 Week Low 2.05
Average Volume 462,242
200-Day Moving Average 4.97
50-Day Moving Average 3.96
20-Day Moving Average 4.04
10-Day Moving Average 4.07
Average True Range 0.05
RSI (14) 59.84
ADX 37.46
+DI 26.07
-DI 12.23
Chandelier Exit (Long, 3 ATRs) 3.97
Chandelier Exit (Short, 3 ATRs) 4.12
Upper Bollinger Bands 4.11
Lower Bollinger Band 3.97
Percent B (%b) 0.66
BandWidth 3.35
MACD Line 0.04
MACD Signal Line 0.06
MACD Histogram -0.0107
Fundamentals Value
Market Cap 181.28 Million
Num Shares 44.6 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -3.03
Price-to-Sales 0.00
Price-to-Book 0.81
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.08
Resistance 3 (R3) 4.08 4.07 4.07
Resistance 2 (R2) 4.07 4.07 4.07 4.07
Resistance 1 (R1) 4.07 4.07 4.07 4.07 4.07
Pivot Point 4.06 4.06 4.06 4.06 4.06
Support 1 (S1) 4.06 4.06 4.06 4.06 4.05
Support 2 (S2) 4.05 4.06 4.05 4.05
Support 3 (S3) 4.05 4.05 4.05
Support 4 (S4) 4.05